Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Novacyt ( (FR:ALNOV) ) has provided an update.
Novacyt announced its monthly update regarding its liquidity agreement with Invest Securities SA, detailing the purchase and sale of ordinary shares during November 2025. The company reported that 6,017 shares were purchased and 4,017 shares were sold under this agreement, with a total of 114,913 shares held in treasury as of the end of November. The update also provided information on the total voting rights, with 70,626,248 ordinary shares in the company. This liquidity agreement, governed by French law, allows Invest Securities to purchase shares on behalf of Novacyt, enhancing the company’s market operations and potentially impacting shareholder interests.
More about Novacyt
Novacyt is an international molecular diagnostics company that offers a wide range of integrated technologies and services, focusing on genomic medicine. The company develops, manufactures, and commercializes molecular assays and instrumentation for various sectors, including human health, animal health, and environmental applications. Novacyt operates through three business segments: Clinical, Instrumentation, and Research Use Only, providing solutions such as in vitro diagnostic products, DNA sample preparation platforms, and qPCR assays. Headquartered in France, Novacyt has a global commercial presence and is listed on the London Stock Exchange’s AIM market and the Paris Stock Exchange Euronext Growth.
Learn more about ALNOV stock on TipRanks’ Stock Analysis page.